Listed

Legend Biotech Corp: Form 20-F for the period ended Dec 31, 2025

Filed with the SEC on Mar 10, 2026 and accepted by EDGAR at Mar 10, 2026, 11:45 ET.

Share

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2025-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2025-01-01 to 2025-12-31$1.03bnifrs-full:RevenueFromContractsWithCustomers
Cost of revenue12 months2025-01-01 to 2025-12-31$397.1mifrs-full:CostOfSales
Operating income12 months2025-01-01 to 2025-12-31−$136.5mifrs-full:ProfitLossFromOperatingActivities
Income tax12 months2025-01-01 to 2025-12-31$14.2mifrs-full:IncomeTaxExpenseContinuingOperations
Net income12 months2025-01-01 to 2025-12-31−$296.8mifrs-full:ProfitLoss
Diluted EPS12 months2025-01-01 to 2025-12-31−$0.81ifrs-full:DilutedEarningsLossPerShare
Basic EPS12 months2025-01-01 to 2025-12-31−$0.81ifrs-full:BasicEarningsLossPerShare
Operating cash flow12 months2025-01-01 to 2025-12-31−$100.2mifrs-full:CashFlowsFromUsedInOperatingActivities
Capital expenditure12 months2025-01-01 to 2025-12-31$28.6mifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
Cash and equivalentsAt period end2025-12-31$901.9mifrs-full:CashAndCashEquivalents
Current assetsAt period end2025-12-31$1.25bnifrs-full:CurrentAssets
Total assetsAt period end2025-12-31$1.73bnifrs-full:Assets
Current liabilitiesAt period end2025-12-31$636.4mifrs-full:CurrentLiabilities
Total liabilitiesAt period end2025-12-31$731.6mifrs-full:Liabilities
Shareholders' equityAt period end2025-12-31$1.00bnifrs-full:Equity
Shares outstandingAt period end2025-12-31369,886,369 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001801198-26-000008. Last ingested by Listed: Nov 10, 2026, 16:50 ET. Listed shows no prices and gives no investment advice.